Close Menu

For almost two years, patients with Fabry's disease have been dealing with severe shortages of the medicine they need — Genzyme's Fabrazyme — as Genzyme deals with manufacturing problems and contamination. A year ago, the patients asked NIH to step in and demand that Genzyme allow other drug companies to make Fabrazyme, a provision known as "march-in" rights that NIH can exercise under certain circumstances according to the Bayh-Dole Act.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.